^
    Apply
    A Study of GB491 in Combination With Letrozole in Patients With HR Positive and HER2 Negative Advanced Breast Cancer (NCT05851014)
    Phase 3
    Genor Biopharma Co., Ltd.
    Recruiting
    Last update posted :
    05/09/2023
    Initiation :
    01/14/2022
    Primary completion :
    01/30/2026
    Completion :
    01/30/2027
    HER-2
    |
    HR positive • HER-2 negative
    |
    letrozole • lerociclib (G1T38)
    G1T38, a CDK 4/6 Inhibitor, in Combination With Fulvestrant in Hormone Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (NCT02983071)
    Phase 1/2
    G1 Therapeutics, Inc.
    Active, not recruiting
    Last update posted :
    02/15/2023
    Initiation :
    01/01/2017
    Primary completion :
    06/01/2023
    Completion :
    10/01/2023
    HER-2
    |
    HR positive • HER-2 negative
    |
    fulvestrant • lerociclib (G1T38)
    GB491 Combined With Fulvestrant for HR+ HER2- Locally Advanced or Metastatic Breast Cancer (LEONARDA-1) (NCT05054751)
    Phase 3
    Genor Biopharma Co., Ltd.
    Recruiting
    Last update posted :
    06/13/2022
    Initiation :
    09/10/2021
    Primary completion :
    10/31/2023
    Completion :
    01/31/2024
    HER-2 • ER
    |
    ER positive • HER-2 negative
    |
    fulvestrant • lerociclib (G1T38)
    A Phase Ib Study of GB491 Plus Letrozole in Patients With Advanced Breast Cancer (NCT05337657)
    Phase 1
    Genor Biopharma Co., Ltd.
    Recruiting
    Last update posted :
    04/20/2022
    Initiation :
    06/02/2021
    Primary completion :
    12/12/2023
    Completion :
    02/01/2024
    HER-2 • ER
    |
    ER positive • HER-2 negative
    |
    letrozole • lerociclib (G1T38)